Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amphastar Pharma
(NQ:
AMPH
)
47.89
+1.37 (+2.94%)
Streaming Delayed Price
Updated: 11:48 AM EDT, Sep 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Amphastar Pharma
< Previous
1
2
3
4
5
Next >
3 Stocks at the Forefront of Medical Innovation
December 25, 2023
Boring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way.
Via
InvestorPlace
Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade
December 21, 2023
On Thursday, Tarsus Pharmaceuticals stock reached a key technical milestone, seeing its Relative Strength Rating jump to 91 from 84.
Via
Investor's Business Daily
Why NASDAQ:AMPH qualifies as a high growth stock.
December 12, 2023
Why the growth investor may take a look at AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH).
Via
Chartmill
TG Therapeutics Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating
December 07, 2023
TG Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 87 to 93.
Via
Investor's Business Daily
Exploring NASDAQ:AMPH's CANSLIM characteristics.
December 05, 2023
Should you consider AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) for growth investing?
Via
Chartmill
These Three Biotech Stocks Are Trading At A Discount
November 23, 2023
Investors exposed to the biotech sector have seen mixed results this year.
Via
Talk Markets
Exploring growth characteristics of AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH).
November 21, 2023
Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock.
Via
Chartmill
Evaluating NASDAQ:AMPH for Growth Investment Opportunities.
November 14, 2023
High growth, ROE and relative strength for AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH), growth investors may appreciate this.
Via
Chartmill
Recap: Amphastar Pharma Q3 Earnings
November 08, 2023
Via
Benzinga
Amphastar Pharmaceuticals Stock Earns Composite Rating Upgrade
November 10, 2023
Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 98 Friday, up from 93 the day before.
Via
Investor's Business Daily
7 Healthcare Stocks That Are Poised to Become the Next Unicorns
November 09, 2023
Discover healthcare stocks with remarkable potential for growth and "unicorn" status in the ever-evolving world of healthcare investments.
Via
InvestorPlace
Disney, Twilio, TransDigm, Marathon Digital And Other Big Stocks Moving Higher On Thursday
November 09, 2023
U.S. stocks traded mostly lower, with the Dow Jones falling around 75 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
CRISPR Therapeutics Stock Earns IBD Stock Rating Upgrade
November 08, 2023
On Wednesday, CRISPR Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85, up from 68 a day earlier.
Via
Investor's Business Daily
Earnings Preview For Amphastar Pharma
November 07, 2023
Via
Benzinga
Amphastar Pharma: Q1 Earnings Insights
May 09, 2023
Via
Benzinga
Earnings Outlook For Amphastar Pharma
May 08, 2023
Via
Benzinga
Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90
October 31, 2023
Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90
October 16, 2023
Revolution Medicines shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
Axsome Therapeutics Stock Clears Key Benchmark, Hits 80-Plus RS Rating
September 27, 2023
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Monday's After-Market Session
September 11, 2023
Via
Benzinga
Eli Lilly (LLY) Stock Up Almost 50% Year to Date: Here's Why
August 17, 2023
Eli Lilly and Company (LLY) boasts a solid portfolio of core drugs in diabetes, autoimmune diseases and cancer.
Via
Talk Markets
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
September 12, 2023
Gainers Tenon Medical, Inc. (NASDAQ: TNON) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offering of shares of its common stock.
Via
Benzinga
Abcam Stock Earns Relative Strength Rating Upgrade
June 20, 2023
A Relative Strength Rating upgrade for Abcam ADR shows improving technical performance.
Via
Investor's Business Daily
FibroGen Stock Joins Rank Of Stocks With RS Ratings Over 90
June 06, 2023
On Tuesday, FibroGen stock saw a positive improvement to its Relative Strength Rating, rising to 94 from 90 a day earlier.
Via
Investor's Business Daily
Inhibrx Stock Showing Improving Market Leadership; Earns 86 RS Rating
May 03, 2023
On Wednesday, Inhibrx stock now clears that desired 80-plus Relative Strength threshold, with a jump from 80 to 86 Wednesday.
Via
Investor's Business Daily
Eli Lilly Divests Low Blood Sugar Drug Baqsimi To Amphastar For $500M Cash
April 24, 2023
Via
Benzinga
Genmab Stock Hits 80-Plus Relative Strength Rating Benchmark
April 17, 2023
On Monday, Genmab stock saw its Relative Strength (RS) Rating jump into the 80-plus percentile, rising to 84, up from 80 the day before.
Via
Investor's Business Daily
Emergent BioSolutions Soars: Analyst Upgrades Stock With Near 100% Upside After FDA's Positive Move
April 10, 2023
Via
Benzinga
BioMarin Pharmaceutical Stock Shows Rising Relative Strength
March 30, 2023
BioMarin Pharmaceutical stock had its Relative Strength Rating upgraded to 77 on Thursday, up from 70 a day earlier.
Via
Investor's Business Daily
Alkermes Stock Sees Rising Relative Strength Rating
March 28, 2023
The Relative Strength (RS) Rating for Alkermes stock climbed into a new percentile Tuesday, as it got a lift from 69 to 77.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.